Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Formulation Matters: The Overlooked Engine of Stability and Success in Antibody-Drug Conjugates.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Pre-formulation development of highly potent nontuberculous mycobacterial agents.

Results in chemistry·2026
Same author

An ultra-long-acting dimeric bictegravir prodrug defined by a short pharmacokinetic tail.

Nature communications·2026
Same author

Co-Encapsulation of Doxorubicin HCl and Paclitaxel in Nanovesicles for Enhanced Breast Cancer Therapy.

AAPS PharmSciTech·2025
Same author

Effects of a Blend of Trisodium Citrate, Creatine Monohydrate, Leucine, and Blueberry Extract on Training-Induced Changes in Leg Extension Strength, Endurance, and Muscle Size.

Journal of dietary supplements·2025
Same author

Liposomes and transferosomes in the delivery of papain for the treatment of keloids and hypertrophic scars.

PloS one·2023

Related Experiment Video

Updated: Apr 24, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.2K

Multifunctional nanoparticles for prostate cancer therapy.

Shantanu S Chandratre1, Alekha K Dash

  • 1Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, 2500 California Plaza, Omaha, Nebraska, 68178, USA.

AAPS Pharmscitech
|September 6, 2014
PubMed
Summary
This summary is machine-generated.

This study developed dual-drug nanoparticles using glyceryl monooleate-chitosan and poly(lactic-co-glycolic) acid polymers to combat cancer recurrence. The polymer type significantly influenced nanoparticle drug release, cytotoxicity, and cellular uptake, offering a promising strategy for combination cancer therapy.

More Related Videos

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

2.7K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

10.8K

Related Experiment Videos

Last Updated: Apr 24, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.2K
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

2.7K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

10.8K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Research

Background:

  • Cancer relapse after initial treatment is often attributed to cancer stem cells.
  • Combination therapy targeting both cancer cells and cancer stem cells is crucial.
  • Nanoparticulate systems enhance drug delivery and tumor targeting for combination therapies.

Purpose of the Study:

  • To develop and characterize a nanoparticulate system encapsulating two distinct anticancer agents, cyclopamine and paclitaxel.
  • To evaluate the efficacy of glyceryl monooleate-chitosan and poly(lactic-co-glycolic) acid nanoparticles for cancer treatment.
  • To investigate the impact of polymer composition on drug release, cytotoxicity, and cellular uptake.

Main Methods:

  • Entrapment of cyclopamine and paclitaxel into glyceryl monooleate-chitosan and poly(lactic-co-glycolic) acid nanoparticles.
  • Characterization of nanoparticle size, zeta potential, and drug crystallinity using thermal analysis.
  • In vitro cytotoxicity assays on DU145, DU145 TXR, and Wi26 A4 cancer cell lines.
  • Assessment of in vitro drug release profiles from both nanoparticle formulations.

Main Results:

  • Glyceryl monooleate-chitosan nanoparticles measured 278.4 nm with positive zeta potential; poly(lactic-co-glycolic) acid nanoparticles measured 234.5 nm with negative zeta potential.
  • Thermal analysis confirmed drugs were in a noncrystalline state within both nanoparticle matrices.
  • Sustained in vitro drug release was observed for both drugs from the nanoparticles.
  • Poly(lactic-co-glycolic) acid blank nanoparticles showed no cytotoxicity, while glyceryl monooleate-chitosan blank nanoparticles exhibited significant cytotoxicity.
  • The choice of polymer significantly influenced nanoparticle in vitro release, cytotoxicity, and cellular uptake.

Conclusions:

  • Nanoparticulate systems effectively co-deliver cyclopamine and paclitaxel, showing potential for combination cancer therapy.
  • The polymer matrix (glyceryl monooleate-chitosan vs. poly(lactic-co-glycolic) acid) critically affects nanoparticle performance, including drug release and cell killing.
  • Further research into polymer selection is vital for optimizing nanoparticulate drug delivery systems against recurrent cancers.